Nevolat vs Wegovy: what's the difference, and does it matter?

Is Nevolat a real, licensed weight-loss medicine in the UK?

No. Searching the MHRA's product database and the GPhC's pharmacy register turns up no authorised UK medicine called Nevolat for weight management. The name circulates on some forums and social-media accounts, sometimes alongside images of injection pens, but the MHRA has been clear that medicines sold online without a traceable, licensed supply chain carry serious risks, counterfeit pens have previously been found to contain the wrong substances entirely. If you've come across Nevolat being offered with no clinical assessment required, that itself is a red flag worth reporting at Yellow Card.

What people searching "nevolat vs wegovy" almost certainly want to understand is Wegovy: whether it works, what the evidence looks like, and how to access it safely. That's what the rest of this page covers, and our Wegovy vs page pulls together the full set of comparisons if you want to explore how it stacks up against other options.

What is Wegovy, and what does the clinical evidence show?

Wegovy is a once-weekly subcutaneous injection of semaglutide, a GLP-1 receptor agonist developed by Novo Nordisk. It is licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. The MHRA granted this licence following the STEP clinical programme; in the STEP 1 trial published in the New England Journal of Medicine, participants taking semaglutide 2.4mg achieved an average body-weight reduction of around 15% over 68 weeks, compared with around 2.4% for placebo, alongside lifestyle changes.

More recently, the MHRA approved a higher 7.2mg maintenance dose (and, on 14 April 2026, a dedicated single-dose 7.2mg pen) which trial data suggests can produce average weight loss of around 20.7% over 72 weeks, narrowing the gap with tirzepatide results. That approval applies to adults with a BMI of 30 or above only. Which dose and pen format might suit you is a clinical decision; specific availability is confirmed at consultation. You can read an overview of the full licensed semaglutide pathway on the NHS semaglutide medicines page.

Wegovy is also distinct from Ozempic, which is semaglutide at a different dose and licensed for type 2 diabetes, not weight management. That distinction matters legally and clinically, and our Wegovy vs Ozempic page covers it in full.

How does Wegovy compare with other licensed UK weight-loss medicines?

The comparison most people are really asking about is between semaglutide (Wegovy) and tirzepatide (Mounjaro). If you're trying to understand how semaglutide relates to Wegovy as a starting point, that page clarifies the relationship before you get into cross-medicine comparisons. A common misconception is that they work in essentially the same way and produce similar results, in fact, there are meaningful differences worth understanding, even if both are effective.

In the SURMOUNT-5 open-label trial, published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. The 7.2mg semaglutide data narrows that gap considerably. Neither result tells you which medicine is right for you, that depends on your health history, any current medicines you take, and what your prescriber finds during assessment.

For a broader look at how semaglutide sits alongside other GLP-1 options, the Wegovy vs GLP-1 medicines page works through the landscape, and Saxenda vs Wegovy covers the liraglutide comparison if that's relevant to you.

How do you access Wegovy through a legitimate UK pharmacy?

Wegovy is a prescription-only medicine. The only legal route to it in the UK is a prescription issued following a proper clinical assessment, a prescriber reviews your health history, BMI, other medicines, and any relevant conditions before deciding whether it is suitable for you. There is no shortcut that keeps you safe.

At nume, the process is straightforward. You complete a free online consultation; a GPhC-registered Independent Prescriber reviews it personally the same day. If treatment is clinically appropriate, it is dispatched the same day (for orders received before 12pm, Monday to Friday) and delivered free the next working day. Every repeat order is reviewed again before anything leaves our pharmacy. You can verify our pharmacy on the GPhC register at registration number 9012878.

On cost: private weight-loss treatment is priced per pen and varies by dose and provider. Since Eli Lilly raised Mounjaro's UK list price from September 2025, typical private market prices for either medicine have ranged roughly £149–£375 per month depending on dose and the provider. For context on what shapes that variation, the Wegovy cost page breaks down what a quoted price should and shouldn't include. One thing worth noting: a substantially lower price for a prescription medicine, especially from a seller you cannot verify on the GPhC register, is not a saving, it is a risk. A small difference in monthly spend is the wrong measure when supply-chain integrity is what keeps you safe.

Which medicine suits you is a clinical decision our prescribers make with you. If you'd like to start that conversation, speak to our prescribers through a free consultation.